Pay in 4 interest-free payments of $5.20 Learn more
Ships within 48 hours · Estimated delivery Oct 29 - Nov 3
No serious adverse events, hospitalization, organ damage, or deaths have been documented in over 100 preclinical studies, even at doses 1,000 times higher than typical therapeutic use
[8] One such potential pathway involves the activation of phospholipase C (PLC), which researchers suggest may lead to the release of inositol triphosphate (IP3) and diacylglycerol (DAG)
Horn, D
The choice of second-line agent depends on individual factors including cardiovascular disease, heart failure, chronic kidney disease, body weight, hypoglycaemia risk, and patient preference
US$ 20.35
US$ 27.17
US$ 28.09
